FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Sodium Pyruvate: 1X Liquid
FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Sodium Pyruvate: 1X Liquid
FluxMPS™ DCP-RPMIGH-P1X is an MPS-grade ultra-filtered cell culture media formulation engineered for organ-on-a-chip (OoC) and microphysiological system (MPS) platforms. Processed through a Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), it delivers approximately 5× lower particulate counts than conventional 0.22 µm–filtered media.
- 0.04μm final filtration
- Endotoxin <0.05 EU/mL
- ISO 13485:2016
- Ultrapure Type 1 water
- ISO Class 5 fill
- Formulation[+] High Glucose, [+] L-Glutamine, [+] Sodium Bicarbonate, [+] 25mM HEPES
- Glucose4500.000 mg/L
- pH (USP <791>)7.4
- Osmolality (USP <785>)Contact for specification
- Endotoxin (USP <85>)< 0.05 EU/mL
- Filtration0.1 µm ×2 + 0.04 µm ×2
- Storage2–8°C, avoid light
- Shelf Life12 months
- ShippingCold pack
- Sizes / Pricing500 mL / 1000 mL
Engineered where standard media fails
Conventional 0.22 µm–filtered media passes mycoplasma, subvisible particulates, and endotoxin fragments that confound cell assays.
Microchannel-safe purity
0.04 µm final filtration; USP <788> particulate compliance. Particle-free media for OoC microfluidic chips.
Total metabolic control
Defined formulation for precise control of carbon sources, nutrients, and metabolic inputs in your experimental system.
Ultrapure-grade water
18.2 MΩ·cm — USP <85> compliant. Eliminates ionic contaminants that alter signaling thresholds.
Low background for imaging
Ultra-low particulate and endotoxin for confocal, biosensor, and live-cell imaging applications on-chip.
Rich, stable nutrient profile
40 verified ingredients per lot. Full CAS traceability. Micro-batch precision manufacturing.
Customization on demand
pH, nutrient concentrations, HEPES, and component modifications available. Contact support@diagnocine.com.
Quadruple-stage filtration system
Four serial filtration stages reaching a final 0.04 µm polish under ISO Class 5 aseptic conditions — the only ready-to-use media at this purity level.
-
1
0.1 µm Pre-filtration I — Large Particulate Removal
Removes large aggregates and debris; protects downstream 0.04 µm membranes and extends their service life.
-
2
0.04 µm Pre-filtration II — Mycoplasma Barrier
Retains mycoplasma (0.1–0.3 µm) — absent from standard 0.22 µm filtration. First sub-mycoplasma polishing stage.
-
3
0.1 µm Sterile-filtration I — Second-pass Redundancy
Second-pass sterility redundancy; ensures no breakthrough from Stage 1. Independent sterility assurance.
-
4
0.04 µm Sterile-filtration II — Final Polish
Ultimate sub-mycoplasma polish; ISO Class 5 aseptic fill & finish. Final product QC release gate.
Performance vs. conventional media
FluxMPS™ DCP-RPMIGH-P1X delivers approximately 5× lower particulate counts than standard 0.22 µm filtered media, with confirmed mycoplasma barrier at every production stage.
© Diagnocine® — DCP-RPMIGH-P1X
OoC and MPS Applications
FluxMPS™ DCP-RPMIGH-P1X delivers ultra-filtered purity for organ-on-a-chip and microfluidic applications.
Automated Bioreactors & Robotics
Optional 0.01 µm (10 nm) ultra-filtered variant available on request for automated bioreactors and robotic perfusion systems.
- Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates that foul automated systems
- Valve & Sensor Protection: Eliminates micro-fouling in automated perfusion and recirculation systems
- Extended Perfusion Stability: Consistent nutrient delivery over long-duration culture runs
Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm ultra-filtered variant.
Micro Physiological System (MPS) & Chip
0.04 µm filtered media for organ-on-a-chip, tissue-on-a-chip, and body-on-a-chip where particle-free media prevents channel fouling.
Cancer Cell Lines & Metabolic Research
Supports NCI-60 cancer lines and Warburg effect metabolic studies with precise nutrient control.
iPSC-Derived Models
Ultra-clean base for iPSC differentiation protocols requiring defined, particulate-free media.
Endothelial & Primary Cells
Particle-free formulation for primary cells and endothelial monolayer studies on-chip.
Metabolic Flux Analysis
Defined formulation for ¹³C isotope tracing, Seahorse XF metabolic assays, and NMR metabolomics.
Microscopy & Optical Sensing
Ultra-low particulate background for confocal microscopy, biosensor measurements, and TEER monitoring on-chip.
Analytical release specifications
Every lot released against the full specification matrix. Certificate of Analysis available: support@diagnocine.com.
| Parameter | Specification |
|---|---|
| Formulation | [+] High Glucose, [+] L-Glutamine, [+] Sodium Bicarbonate, [+] 25mM HEPES |
| Appearance | Red-colored, clear solution |
| Total ingredients | 40 |
| pH USP <791> | 7.4 |
| Osmolality USP <785> | Contact for specification |
| Glucose | 4500.000 mg/L |
| Parameter | Specification |
|---|---|
| Endotoxin USP <85> BET | < 0.05 EU/mL |
| Sterility USP <71> | No growth / 14 days |
| Mycoplasma | Negative (0.04 µm barrier) |
| Particulate ≥10 µm USP <788> | NMT 25/mL |
| Particulate ≥25 µm USP <788> | NMT 3/mL |
| Water purity | Type 1, 18.2 MΩ·cm |
| Manufacturing std. ISO | ISO 13485:2016 |
| Fill environment | ISO Class 5 (Class 100) |
| Parameter | Specification |
|---|---|
| Storage temperature | 2–8°C, away from light |
| Freeze-thaw | Do not freeze |
| Shelf life | 12 months from manufacture |
| Shipping condition | Cold pack |
| CO₂ requirement | 5% CO₂ required |
| Parameter | Specification |
|---|---|
| Raw material grade | Reagent / cell culture grade |
| Traceability | Full lot traceability per ISO 13485 |
| Manufacturing QMS ISO | ISO 13485:2016 certified |
| Regulatory alignment | 21 CFR Part 820 (cGMP) aligned |
| Production method | Micro-batch, per-lot QC release |
| Intended use | Research Use Only (RUO) |
Full composition (mg/L)
RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Sodium Pyruvate: 1X Liquid: 40 ingredients verified per lot with CAS numbers for full raw-material traceability. All ingredients from the original formulation are preserved exactly.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium nitrate tetrahydrate | 13477-34-4 | 100.000 |
| Magnesium sulphate anhydrous | 7487-88-9 | 48.840 |
| Potassium chloride | 7447-40-7 | 400.000 |
| Sodium bicarbonate | 144-55-8 | 2000.000 |
| Sodium chloride | 7647-14-5 | 6000.00 |
| Sodium phosphate dibasic anhydrous | 7558-79-4 | 800.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| Glycine | 56-40-6 | 10.000 |
| L-Arginine hydrochloride | 1119-34-2 | 241.000 |
| L-Asparagine | 70-47-3 | 50.000 |
| L-Aspartic acid | 56-84-8 | 20.000 |
| L-Cystine dihydrochloride | 30925-07-6 | 65.200 |
| L-Glutamic acid | 56-86-0 | 20.000 |
| L-Glutamine | 56-85-9 | 300.000 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 20.960 |
| L-Hydroxyproline | 51-35-4 | 20.000 |
| L-Isoleucine | 73-32-5 | 50.000 |
| L-Leucine | 61-90-5 | 50.000 |
| L-Lysine hydrochloride | 657-27-2 | 40.000 |
| L-Methionine | 63-68-3 | 15.000 |
| L-Phenylalanine | 63-91-2 | 15.000 |
| L-Proline | 147-85-3 | 20.000 |
| L-Serine | 56-45-1 | 30.000 |
| L-Threonine | 72-19-5 | 20.000 |
| L-Tryptophan | 73-22-3 | 5.000 |
| L-Tyrosine Disodium Salt | 69847-45-6 | 28.830 |
| L-Valine | 72-18-4 | 20.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Choline chloride | 67-48-1 | 3.000 |
| D-Biotin | 58-85-5 | 0.200 |
| D-Ca-Pantothenate | 137-08-6 | 0.250 |
| Folic acid | 59-30-3 | 1.000 |
| Niacinamide | 98-92-0 | 1.000 |
| Pyridoxine hydrochloride | 58-56-0 | 1.000 |
| Riboflavin | 83-88-5 | 0.200 |
| Thiamine hydrochloride | 67-03-8 | 1.000 |
| i-Inositol | 87-89-8 | 35.000 |
| p-Amino benzoic acid (PABA) | 150-13-0 | 1.000 |
| OTHERS | ||
| D-Glucose | 50-99-7 | 4500.000 |
| Glutathione reduced | 70-18-8 | 1.000 |
| HEPES | 7365-45-9 | 5958.000 |
| Phenol red sodium salt | 34487-61-1 | 5.300 |
ISO 13485 Manufacturing & Compliance
Every batch of FluxMPS™ DCP-RPMIGH-P1X is manufactured under a certified ISO 13485:2016 QMS with full lot traceability and multi-parameter QC release testing.
ISO 13485:2016 QMS
Full quality management system with documented procedures, deviation control, and CAPA. Every lot traceable from raw material to final release.
Ultrapure Type 1 Water
18.2 MΩ·cm resistivity. USP <85> compliant. Eliminates ionic contamination at the manufacturing source.
ISO Class 5 Fill & Finish
Final aseptic filling in ISO Class 5 (Class 100) cleanroom. Immediate post-filtration fill to prevent recontamination.
Micro-Batch Precision
Small-batch manufacturing with per-lot QC release. Every batch tested independently — not pooled or blended across lots.
Endotoxin USP <85> BET
LAL-based endotoxin test per lot. Release criterion: < 0.05 EU/mL. Below TLR4 activation threshold for immune cell assays.
Particulate USP <788> Method 2
Light obscuration particulate analysis. NMT 25/mL at ≥10 µm; NMT 3/mL at ≥25 µm. Compliant with injectable-grade standards.
Osmolality USP <785>
Osmolality verified per lot using vapor pressure or freezing-point depression osmometry per USP <785>.
Documentation / CoA
Full Certificate of Analysis available per lot. Includes all QC parameters, test dates, and raw material lot numbers. Request: support@diagnocine.com.
How DCP-RPMIGH-P1X compares
FluxMPS™ versus conventional 0.22 µm filtered media for OoC and MPS applications.
| Parameter | DCP-RPMIGH-P1X (FluxMPS™) | Conventional 0.22 µm Filtered | Standard Alternative |
|---|---|---|---|
| Formulation | [+] High Glucose, [+] L-Glutamine, [+] Sodium Bicarbonate, [ | Standard RPMI 1640 | Standard RPMI 1640 |
| Final filtration pore size | 0.04 µm | 0.22 µm | 0.22 µm |
| Number of filtration stages | 4 stages | 1 stage | 1–2 stages |
| Mycoplasma barrier filtration | check_circle | cancel | cancel |
| Endotoxin specification | < 0.05 EU/mL | Variable | < 1 EU/mL typical |
| USP particulate compliance | check_circle | cancel | cancel |
| Water quality | Type 1, 18.2 MΩ·cm | Type 2 typical | Type 2 typical |
| Manufacturing QMS | ISO 13485:2016 | ISO 9001 typical | Variable |
| Microfluidic channel compatibility | check_circle | cancel | cancel |
| Custom formulation | check_circle | cancel | Limited |
Frequently asked questions
Common questions about FluxMPS™ DCP-RPMIGH-P1X and its use in OoC and MPS applications.
Supporting literature
Curated peer-reviewed references relevant to ooc and mps applications and FluxMPS™ ultra-filtered cell culture media applications.
- Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nature Biotechnology. 2014;32(8):760–772.doi:10.1038/nbt.2989
- Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in biomedical research. Nature. 2014;507(7491):181–189.doi:10.1038/nature13118
- Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
- Ingber DE. Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? Advanced Science. 2020;7(22):2002162.doi:10.1002/advs.202002162
- Maoz BM, et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic landscape of brain disease. Nature Biotechnology. 2018;36:865–874.doi:10.1038/nbt.4226
- Bhise NS, et al. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 2016;8(1):014101.doi:10.1088/1758-5090/8/1/014101
- Luni C, Serena E, Elvassore N. Human-on-chip for therapy development and fundamental science. Current Opinion in Biotechnology. 2014;25:45–50.doi:10.1016/j.copbio.2013.08.015
- Erickson KA, Bhansali S. Mycoplasma contamination in cell cultures: a survey of incidence and approaches to prevention. Journal of the Association for Laboratory Automation. 2012;17(5):346–354.doi:10.1177/2211068212456089
- van Duinen V, et al. Microfluidic 3D cell culture: from tools to tissue models. Current Opinion in Biotechnology. 2015;35:118–126.doi:10.1016/j.copbio.2015.05.002
- Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.doi:10.1126/science.123.3191.309
